Jazz Pharmaceuticals
Jazz Pharmaceuticals PLC is an Ireland-based biopharmaceutical company focused on developing and commercializing medicines in neuroscience and oncology. The company's product portfolio includes treatments for sleep disorders such as narcolepsy and idiopathic hypersomnia, severe pediatric epilepsies, and haematology or oncology conditions. Core revenue drivers stem from global sales of flagship proprietary prescription products including Xywav, Xyrem, Epidiolex, and Rylaze. Principal end markets serve specialized medical prescribers, sleep centers, oncology clinics, and patients managing rare or complex medical conditions globally. Jazz Pharmaceuticals holds a world-leading market position in sleep medicine therapies and cannabinoid-based pharmaceuticals. Jazz Pharmaceuticals PLC is headquartered in Dublin, Ireland, and its ordinary shares are traded on the Nasdaq under the ticker symbol JAZZ.
23 of the funds FundTelligence covers report a position in Jazz Pharmaceuticals.
- Legal name
- Jazz Pharmaceuticals PLC
- Sector
- Health Care
- Country
- Ireland
- Funds holding it
- 23
Funds holding Jazz Pharmaceuticals
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 5.02 % (full portfolio disclosed, September 2026)
- Fondita Global Small Cap — Fondita · 4.9 % (largest positions only, October 2026)
- BNP Health Care Innovators — BNP Paribas · 3.64 % (full portfolio disclosed, June 2026)
- Pensum Kairos — Pensum · 1.99 % (full portfolio disclosed, June 2026)
- Swedbank Robur Healthcare — Swedbank · 1.65 % (full portfolio disclosed, October 2026)
- Lannebo Global — Lannebo · 1.28 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.2 % (full portfolio disclosed, October 2026)
- Franklin U.S. Opportunities Fund — Franklin Templeton · 1.07 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 23 funds holding it.